- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory multiple myeloma (RRMM)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1104KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 103KB)
Elotuzumab – July 2021
Elotuzumab: Powder for I.V. infusion 300 mg, Powder for I.V. infusion 400 mg; Empliciti®
Last updated
29 October 2021